Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

July 29, 2015 12:06 AM ET


Company Overview of Enteris BioPharma, Inc.

Company Overview

Unigene Laboratories Inc., Peptelligence(TM) Drug Delivery Platform and Certain Assets comprises Peptelligence™ drug delivery, recombinant manufacturing platforms, and company’s Biotechnologies Strategic Business Unit. Peptelligence offers intellectual property covering drug delivery and manufacturing technologies, peptide research and development, and proprietary know-how.


United States

Key Executives for Enteris BioPharma, Inc.

President and Chief Financial Officer
Age: 51
Vice President of Business Development
Compensation as of Fiscal Year 2015.

Enteris BioPharma, Inc. Key Developments

Enteris BioPharma, Inc. Announces Board Changes

Enteris BioPharma, Inc. announced the appointment of Steven J. Brickner, Ph.D., Jonathan Chernoff, MD, Ph.D., and Waleed Danho, Ph.D to the company's Scientific Advisory Board. Dr. Brickner joins Enteris' Scientific Advisory Board as an expert in synthetic organic/medicinal chemistry and the discovery of novel antibacterial agents. Dr. Chernoff is an internationally recognized expert in signal transduction, with particular interest in the regulation of cell proliferation and movement by protein kinases and phosphatases. Currently the Chief Scientific Officer at the Fox Chase Cancer Center. Dr. Danho joins Enteris as one of the foremost leaders in the discovery of peptide-based drugs, peptide mimetics, and conformationally restricted peptides. Most recently the Distinguished Research Leader at Hoffmann-La Roche Inc.

Enteris BioPharma, Inc. and KeyBioScience Enter Strategic Licensing Agreement

Enteris BioPharma, Inc. and KeyBioScience announced a strategic licensing agreement for Enteris' oral drug delivery and recombinant manufacturing technologies to advance the development of KeyBioScience's recently acquired family of proprietary metabolic peptides for various indications, including the treatment of Type 2 diabetes, obesity and other inflammatory conditions with high unmet medical and socioeconomic needs. For KeyBioScience, the licensing agreement signals its transition to a clinical stage company following its formation by Nordic Bioscience. Under the terms of the agreement, Enteris will license to KeyBioScience its oral drug delivery and recombinant manufacturing technologies, as well as become the exclusive provider of pre-clinical and clinical trial API and solid dosage form finished product and will receive both fee-for-service revenues and royalties based on net sales of the developed products.

Enteris BioPharma, Inc. Appoints Timothy J. Saxon as Vice President of Business Development

Enteris BioPharma, Inc. announced the appointment of Timothy J. Saxon as Vice President of Business Development. Mr. Saxon will serve as a member of Enteris' executive leadership team and lead partnering and licensing efforts to advance the clinical development and market expansion of the company's industry leading oral peptide and small molecule delivery platform. Most recently, Mr. Saxon was an Associate Partner with Alacrita Consulting where he consulted for a range of small pharma and biotech companies, providing international business development capabilities. Prior to Alacrita, Mr. Saxon was Vice President, Business Development for Arecor Ltd., a drug technology company focused on improving the delivery of proteins and biological therapies. While at Arecor, Mr. Saxon led the company's business development activities and was responsible for securing six out-licensing deals and more than a dozen collaborations with major pharma companies. Mr. Saxon's career is also highlighted by global business development positions at Novartis Pharmaceuticals and Wyeth. During his tenure at Novartis, Mr. Saxon was responsible for driving the growth of its Cardiovascular Medicine and Metabolic Dysfunction business; and at Wyeth, Mr. Saxon held numerous positions of increasing authority over a seven-year period in which he led the company's international business development and was credited with implementing innovation initiatives that enabled Wyeth to more efficiently identify and act upon new product opportunities. Mr. Saxon has also held business development positions at Sagentia Ltd., Boots Pharmaceuticals (now Abbott), and ICI Pharmaceuticals (now AstraZeneca).

Similar Private Companies By Industry

Company Name Region
SerOptix, Inc. United States
Ambio Holdings, Inc. United States
Stem Cell Innovations, Inc. United States
Selventa, Inc. United States
SteadyMed Therapeutics, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Enteris BioPharma, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at